Entity Dossier
entity

Pharmacia

Strategic Concepts & Mechanics

Cornerstone MoveGlobal Expansion from a Small-Country Base
Capital StrategyLand and Forest as Parallel Wealth Store
Signature MoveSpin-Off to Multiply, Never Conglomerate
Strategic PatternDrug Repurposing as Market Expansion
Cornerstone MoveControl Architecture Over Capital Efficiency
Risk DoctrineDebt Aversion from Farming Roots
Capital StrategyCrisis-Price Entry as Wealth Origin
Capital StrategyMultiple Expansion Through Proven Ownership
Signature MoveBack the CEO, Never Touch the Controls
Signature MoveFlee the State to Protect the Company
Cornerstone MoveEternal Horizon, Never Sell the Core
Signature MoveBuy at 'Nice Price Tags' During Crisis
Cornerstone MoveGenerational Transfer as Strategic Design, Not Inheritance
Signature MoveExplorer-Billionaire: Eight Poles as Identity
Signature MovePeptide Hormone Bet Held for Seven Decades
Competitive AdvantagePhilanthropy as Market-Building
Signature MoveSavén: Educate the Market Before You Can Sell To It
Operating PrincipleClear-Cut Forestry vs Regrowth Capitalism
Signature MoveJonsson: Wallenberg Network as Entry Ticket
Signature MoveMix: Shotgun Weddings Then Velvet-Rope Fundraising
Strategic PatternDeregulation as Deal-Flow Gold Rush
Capital StrategySecondaries: Passing Companies Between PE Funds
Cornerstone MoveDouble Profitability or Don't Enter
Cornerstone MoveHunt Corporate Orphans After Deregulation
Competitive AdvantageCanadian Pension Model: Kill the Middleman
Identity & CultureSwedish Hero Immunity for Visible Founders
Signature MoveKarlsson: Ratos as the Anti-Fund — Hold Seventeen Years If Needed
Risk DoctrineShort-Termism Trap: Five-Year Horizon vs Ten-Year Payoff
Signature MoveDahlström: Low Leverage, Family Businesses, Patient Capital
Cornerstone MoveDebt as the Engine, Company Pays Its Own Ransom
Signature MoveAhlström: Copenhagen Office to Dodge Swedish Capital Controls
Cornerstone MoveFee Airbag: Get Paid Win or Lose

Primary Evidence

"Frederik and Eva Paulsen were pioneers in developing and selling drugs based on peptide hormones, which are small proteins secreted into the bloodstream from the pituitary gland. Eva Paulsen had experience in the field through previous research assignments. She had experimented with peptide hormones during her time at Pharmacia and Organon in Stockholm. Frederik and Eva Paulsen were convinced that the natural origin of peptide hormones could provide a more suitable basis for drug development than the steroids other companies were working with in the 1950s. They acquired a house in Malmö where they established a research department. In 1961, the research team made a major breakthrough when they learned to produce the peptide hormones vasopressin, also called antidiuretic hormone (ADH), and oxytocin synthetically and on an industrial scale. Ferring was one of the first companies in the world to succeed in this. The pharmaceutical company intended to treat diabetes insipidus (DI), not diabetes mellitus, which is commonly referred to as sugar sickness. DI increases urine production, which can lead to dehydration and pose a life-threatening risk if not treated. The synthetically manufactured drugs had fewer side effects, and the company was no longer dependent on the supply of pig pituitaries. After nearly seven decades, it has proven that the investment was right. To this day, peptide hormones are used in several of Ferring’s drugs."

Source:Sweden's Most Powerful Families - The Companies, the People, the Money

"Volvo’s then-CEO PG Gyllenhammar, who for many years was considered Sweden’s most powerful person, was one of those who bought into this reasoning. Among other things, he added the food company Procordia and the pharmaceutical company Pharmacia to his automobile business. A group like the forestry company Stora owned Swedish Match, which in turn not only produced matches, but also building materials, flooring, cardboard, and machines for fish gutting. Nokia manufactured such diverse products as televisions and rubber boots."

Source:The Finance Princes - The Story of the Swedish Venture Capitalists

Appears In Volumes